Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma

Fig. 3

The NRP inhibitor NRPa-308 inhibits ccRCC cell proliferation more efficiently than sunitinib and EG00229. The effects of NRPa-308, sunitinib and the commercially available NRP inhibitor (EG00229) measured by MTT assays, were tested in (a) 786-O cells, (b) on A498 cells and (c) on HDF cells. d Determination of the IC50 for each treatment in the different cell lines and their selectivity index. *p < 0.05; **p < 0.01; *** p < 0.001

Back to article page